Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00498901 · ClinicalTrials.gov registry record · Phase 2
Letrozole and Goserelin or Leuprolide in Treating Premenopausal Estrogen Receptor-Positive Patients With Stage IV Breast Cancer
A Phase 2 study, sponsored by University of Washington.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT00498901 is a Phase 2 study that was terminated before completion, run by University of Washington. The registered enrollment target is 1 participants.
The verdict
NCT00498901, a Phase 2 study, was terminated before completion, sponsored by University of Washington.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
RATIONALE: Aromatase inhibitors, such as letrozole, prevent the formation of estradiol, a female hormone. Giving letrozole together with goserelin, leuprolide, or surgery may be an effective treatment in women with hormone-dependent breast cancer. PURPOSE: This phase II trial is studying how well giving letrozole together with goserelin or leuprolide works in treating premenopausal estrogen receptor-positive patients with stage IV breast cancer.
Interventions
- DRUG letrozole
- DRUG leuprolide acetate
- DRUG goserelin
- PROCEDURE conventional surgery
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2007-02 |
| Est. Completion | 2008-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00498901
The ClinicalTrials.gov registry entry for NCT00498901 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which letrozole is the first listed.
NCT00498901 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00498901 about?
NCT00498901 is a clinical study titled "Letrozole and Goserelin or Leuprolide in Treating Premenopausal Estrogen Receptor-Positive Patients With Stage IV Breast Cancer". RATIONALE: Aromatase inhibitors, such as letrozole, prevent the formation of estradiol, a female hormone. Giving letrozole together with goserelin, leuprolide, or surgery may be an effective treatment in women with hormone-dependent breast cancer. PURPOSE: This phase II trial is studying how well g...
What is the current status of trial NCT00498901?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2007-02. Estimated completion is 2008-11.
What interventions are being tested in trial NCT00498901?
The interventions under investigation include: letrozole (DRUG), leuprolide acetate (DRUG), goserelin (DRUG), conventional surgery (PROCEDURE).
Who is sponsoring clinical trial NCT00498901?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.